novo-nordisk

Documente

Media

New Model Needed in Diabetes Care

Ryzodeg® Offers Improved glycaemic Control With Significantly Lower Rates of Hypoglycaemia Compared to biphasic insulin aspart 30 in Adults With Type 2 Diabetes[1]

Documente

Media

Ryzodeg® Offers Improved glycaemic Control With Significantly Lower Rates of Hypoglycaemia Compared to biphasic insulin aspart 30 in Adults With Type 2 Diabetes[1]

Novo Nordisk se sitúa en el puesto 4 entre los Top 20 Science Employers del mundo

Documente

Media

Novo Nordisk se sitúa en el puesto 4 entre los Top 20 Science Employers del mundo

Novo Nordisk se classe au 4ème rang des 20 meilleurs employeurs au monde dans le domaine des sciences

Documente

Media

Novo Nordisk se classe au 4ème rang des 20 meilleurs employeurs au monde dans le domaine des sciences

Novo Nordisk Ranks 4th Among the World s Top 20 Science Employers

Documente

Media

Novo Nordisk Ranks 4th Among the World's Top 20 Science Employers

Investigational Ultra-long-acting Insulin Degludec Reduces Rates of Nocturnal Hypoglycaemia in Type 2 Diabetes Patients Versus Insulin Glargine

Documente

Media

Investigational Ultra-long-acting Insulin Degludec Reduces Rates of Nocturnal Hypoglycaemia in Type 2 Diabetes Patients Versus Insulin Glargine

Publicații

Filtrează după

Sortează

YouScribe

Catalogul

Serviciul

Condițiile